In order to effectively handle collection and analysis of huge volumes of vital data, a leader from IQVIA advises bringing on people up to the challenge.
The first round of job cuts at a solid oral dose facility in Broomfield, Colorado earmarked for closure has taken place, says Novartis subsidiary Sandoz.
High turnover rates among clinical research associates (CRA) continue to plague the industry – and competence and staff engagement are the "crux" of the issue, says IAOCR.
Salary increases will only help CROs hold on to staff for so long according to the author of a wages study who says retention is ultimately about building loyalty.
The CEO of Immuno Biotech who said he only employs “beautiful women” and noted a candidate’s lipstick and high heels on her job application has been fined for sex discrimination.
Trial participant payment tech firm Greenphire has moved to a new Philadelphia headquarters to add capacity and plans to hire 40 more staff by the end of the year.
Northern Ireland-based contractor Almac will create 348 jobs over the next five years in its pharma and clinical services business according to UK enterprise, trade and investment Minister, Arlene Foster.
Research Pharmaceutical Services' (RPS) former chief information officer (CIO) claims he was unfairly dismissed after discovering the CRO was unlawfully storing potential employees' personal data.
Wuxi PharmaTech finished the fourth quarter and the full year 2010 on a high driven by growth across all business units and the payoff from former suitor Charles River Laboratories (CRL).
GlaxoSmithKline has told its workforce that 55 jobs will be axed at its manufacturing base in Currabinny, Co Cork, and 66 jobs will be lost as a result of revised shift-working plans.
Massachusetts-based Pharmalucence is constructing a 70,000 sq ft production facility to boost the contract manufacturing capacity it can offer local biotechs.
More than 50 per cent of large pharma keep all pharmacovigilance in-house but among smaller firms, and even some big businesses, outsourcing is considerable, according to a new report.
DSM Speciality Intermediates (DSI) is to close by the end of 2010, with activities at its production site ceasing in July, in response to pricing pressures caused by the rise of rivals in India and China.
Senator Chuck Grassley has written a letter to Andrew von Eschenbach alleging systemic mismanagement of employee pay and benefits at the US Food and Drug Administration (FDA).
